Rebecca Pace, NP
Family · Chesapeake, VANPI 1427596568
Payments from drug & device makers
Across 435 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$890
- Dexcom, Inc.$550
- Bayer$445
- Boehringer Ingelheim$428
- Radius Health, Inc.$417
- plus $5K from 32 others
What the payments were for
- Food & beverage$8,391100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 84 | $1,123 |
| Novo Nordisk | 56 | $890 |
| Dexcom, Inc. | 27 | $550 |
| Bayer | 19 | $445 |
| Boehringer Ingelheim | 23 | $428 |
| Radius Health, Inc. | 17 | $417 |
| Xeris Pharmaceuticals, Inc. | 23 | $416 |
| Amgen(2 entities) | 20 | $412 |
| Mannkind Corporation | 22 | $374 |
| AstraZeneca(2 entities) | 7 | $342 |
| Corcept Therapeutics | 13 | $311 |
| Sanofi-aventis U.S. LLC | 13 | $305 |
| Insulet Corporation | 15 | $304 |
| Abbott | 11 | $236 |
| AbbVie | 14 | $224 |
| Cequr Corporation | 2 | $164 |
| Pfizer | 7 | $145 |
| Medtronic | 5 | $144 |
| Kyowa Kirin, Inc. | 6 | $138 |
| Recordati_rare_diseases_inc. | 7 | $128 |
| Merck | 7 | $120 |
| Lifescan, Inc. | 4 | $119 |
| Amneal Pharmaceuticals LLC | 5 | $106 |
| Ascendis Pharma Endocrinology Inc | 4 | $83 |
| BETA Bionics, Inc. | 5 | $60 |
| Sequel Med Tech, LLC | 2 | $53 |
| Tandem Diabetes Care, Inc. | 2 | $48 |
| IBSA Pharma Inc. | 2 | $47 |
| Embecta Corp. | 1 | $46 |
| Ultragenyx Pharmaceutical Inc. | 2 | $43 |
| Zealand Pharma US, Inc. | 2 | $39 |
| Tolmar, Inc. | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Ascensia Diabetes Care US Inc. | 1 | $26 |
| Novartis | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Clarus Therapeutics Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$252
- CeQur Simplicity$136
- Kerendia$125
- DEXCOM G6 TRANSMITTER$102
How this compares
$8,410 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 260 | $432,593 |
| MounjaroTirzepatide | 187 | $318,176 |
| JardianceEmpagliflozin | 200 | $250,225 |
| TrulicityDulaglutide | 122 | $213,840 |
| Humalog Kwikpen U-200Insulin Lispro | 38 | $153,278 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 75 | $90,404 |
| FarxigaDapagliflozin Propanediol | 50 | $58,732 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 90 | $52,967 |
| AfrezzaInsulin Regular, Human | 22 | $49,900 |
| JanuviaSitagliptin Phosphate | 38 | $45,381 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $37,003 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 38 | $34,048 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 12 | $33,760 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $32,425 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 196 | $31,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro, Humalog Mix 75-25 | $1,123 | $557,103435 claims |
| Novo NordiskOzempic, Fiasp, Novolog, Novolog Mix 70-30 | $890 | $476,731329 claims |
| Boehringer IngelheimJardiance, Tradjenta | $428 | $270,406214 claims |
| MerckJanuvia, Janumet Xr | $120 | $60,09651 claims |
| AstraZenecaFarxiga | $342 | $58,73250 claims |
| Mannkind CorporationAfrezza | $374 | $49,90022 claims |
| Sanofi-aventis U.S. LLCLantus | $305 | $4,26318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Chesapeake
- Jarrod ElsassChesapeake$11K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.